Primary breast and primary female genital tract DLBCLs also express similar biological mechanisms, with MYD88 mutations observed in 71% and 50% of cases, respectively, while CD79B mutations were reported in 37% of primary breast and female genital tract DLBCL cases [54]. This evidence concerns the gene MYD88 and diffuse large B-cell lymphoma.